SCHEMBL2768112

SCHEMBL2768112

CCN(CC)C(=O)N1CCN(c2ccc(O)c(F)c2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.45
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 3/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MAPT P10636 2/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
MAPK1 P28482 2/20 0.40
POLB P06746 1/20 0.40
HTT P42858 1/20 0.40
ADAMTS5 Q9UNA0 2/20 0.40
MMP13 P45452 1/20 0.40
ADAM17 P78536 1/20 0.40
ACACB O00763 1/20 0.39
ACACA Q13085 1/20 0.39
MMP2 P08253 1/20 0.39
RORC P51449 1/20 0.39
CYP2D6 P10635 1/20 0.39
DRD2 P14416 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11057047 0.82 ALDH1A1 (0.58) HTR1AKDM4EALDH1A1KMT2AMAPT
SCHEMBL5262415 0.80 GFER (0.55) KDM4EKMT2AMAPTGAARORC
SCHEMBL2768117 0.78 CNR1 (0.56) KDM4EALDH1A1KMT2AMAPTLMNA
SCHEMBL10144140 0.77 MAPT (0.63) HTR1AKDM4EALDH1A1KMT2ATDP1
SCHEMBL2767656 0.77 KDM4E (0.46) HTR1AKDM4EALDH1A1TDP1MAPT
SCHEMBL11051087 0.76 HRH3 (0.57) HTR1AALDH1A1KMT2AMAPTLMNA
SCHEMBL11059226 0.76 AKR1C3 (0.54) HTR1AKDM4EALDH1A1KMT2ATDP1
SCHEMBL11051848 0.76 HRH3 (0.56) HTR1AALDH1A1KMT2AMAPTLMNA
SCHEMBL11051123 0.76 HTR1A (0.61) HTR1AALDH1A1KMT2AMAPTLMNA
SCHEMBL11052895 0.75 MAPT (0.58) HTR1AKDM4EALDH1A1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1627871-B1 CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE ASKA PHARM CO LTD (JP) 2010-04-14 EP disclosed
CN-100467449-C Cyclic aminophenyl sulfamate derivative ASKA PHARM CO LTD (JP) 2009-03-11 CN disclosed
US-7449466-B2 Cyclic aminophenyl sulfamate derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2008-11-11 US disclosed
US-20060189625-A1 Cyclic aminophenyl sulfamate derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2006-08-24 US disclosed
CN-1823039-A Cyclic aminophenyl sulfamate derivative ASKA PHARM CO LTD (JP) 2006-08-23 CN disclosed
EP-1627871-A1 CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE Teikoku Hormone Mfg. Co., Ltd. (JP) 2006-02-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189625-A1 Cyclic aminophenyl sulfamate derivative SHBG, STS, ARSA HTR1A 2511/4885KDM4E 692/4885ALDH1A1 2953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.